CC BY-NC-ND 4.0 · Int Arch Otorhinolaryngol 2019; 23(03): e325-e330
DOI: 10.1055/s-0039-1688968
Original Research
Thieme Revinter Publicações Ltda Rio de Janeiro, Brazil

Prescription Profile and Clinical Outcomes in Patients with Allergic Rhinitis Treated with Oral Antihistamines or Nasal Corticosteroids

1   Department of Research, Soluciones Integrales para la Investigación y la Educación en Salud (SIIES), Bogotá, Colombia
2   Fundación Universitaria de Ciencias de la Salud-FUCS, Bogotá, Colombia
,
Carlos Castro
1   Department of Research, Soluciones Integrales para la Investigación y la Educación en Salud (SIIES), Bogotá, Colombia
2   Fundación Universitaria de Ciencias de la Salud-FUCS, Bogotá, Colombia
› Author Affiliations
Further Information

Publication History

27 December 2017

13 April 2019

Publication Date:
28 May 2019 (online)

Abstract

Introduction Oral antihistamines and intranasal corticosteroids have been shown to be effective and safe for the treatment of allergic rhinitis; however, the evidence suggests a level of superiority of corticosteroids, so they should be preferred over the former.

Objective To know the prescription profile of two second generation antihistamines (cetirizine and levocetirizine) and two nasal corticosteroids (mometasone and furoate-ciclesonide) in a cohort of patients with allergic rhinitis, and to compare the clinical outcomes obtained.

Methods A cohort study was carried including patients with allergic rhinitis treated with cetirizine, levocetirizine, mometasone furoate or ciclesonide. The improvement was evaluated with the total nasal symptoms score (TNSS). This scale yields results between 0 and 12. Zero indicates absence of symptoms.

Results A total of 314 patients completed 12 weeks of follow-up. Seventy-five percent were treated with antihistamines, 20% with corticosteroids, and 5% with a combination of the above. The TNSS median for corticosteroid was 2.5 points; for antihistamines, its was 5 points, and for combination, it was 4 points. We found differences between corticosteroids and antihistamines.

Conclusion The prescription percentage of second generation oral antihistamines is higher than that of intranasal corticosteroids. However, patients with allergic rhinitis treated with the second option obtained better control of symptoms.

 
  • References

  • 1 Bousquet J, Khaltaev N, Cruz AA. , et al; World Health Organization; GA(2)LEN; AllerGen. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy 2008; 63 (Suppl. 86) 8-160
  • 2 Aït-Khaled N, Pearce N, Anderson HR, Ellwood P, Montefort S, Shah J. ; ISAAC Phase Three Study Group. Global map of the prevalence of symptoms of rhinoconjunctivitis in children: The International Study of Asthma and Allergies in Childhood (ISAAC) Phase Three. Allergy 2009; 64 (01) 123-148
  • 3 Pace WD, Dickinson LM, Staton EW. Seasonal variation in diagnoses and visits to family physicians. Ann Fam Med 2004; 2 (05) 411-417
  • 4 Brożek JL, Bousquet J, Agache I. , et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines-2016 revision. J Allergy Clin Immunol 2017; 140 (04) 950-958
  • 5 Plaut M, Valentine MD. Clinical practice. Allergic rhinitis. N Engl J Med 2005; 353 (18) 1934-1944
  • 6 Brozek JL, Bousquet J, Baena-Cagnani CE. , et al; Global Allergy and Asthma European Network; Grading of Recommendations Assessment, Development and Evaluation Working Group. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 revision. J Allergy Clin Immunol 2010; 126 (03) 466-476
  • 7 Passali D, Spinosi MC, Crisanti A, Bellussi LM. Mometasone furoate nasal spray: a systematic review. Multidiscip Respir Med 2016; 11: 18
  • 8 Rodríguez-Martínez CE, Sossa-Briceño MP, Vladimir Lemos E. Cost-effectiveness analysis of mometasone furoate versus beclomethasone dipropionate for the treatment of pediatric allergic rhinitis in Colombia. Adv Ther 2015; 32 (03) 254-269
  • 9 Downie SR, Andersson M, Rimmer J. , et al. Symptoms of persistent allergic rhinitis during a full calendar year in house dust mite-sensitive subjects. Allergy 2004; 59 (04) 406-414
  • 10 Juel-Berg N, Darling P, Bolvig J. , et al. Intranasal corticosteroids compared with oral antihistamines in allergic rhinitis: A systematic review and meta-analysis. Am J Rhinol Allergy 2017; 31 (01) 19-28
  • 11 Okubo K, Kurono Y, Ichimura K. , et al; Japanese Society of Allergology. Japanese guidelines for allergic rhinitis 2017. Allergol Int 2017; 66 (02) 205-219
  • 12 Feng S, Fan Y, Liang Z, Ma R, Cao W. Concomitant corticosteroid nasal spray plus antihistamine (oral or local spray) for the symptomatic management of allergic rhinitis. Eur Arch Otorhinolaryngol 2016; 273 (11) 3477-3486
  • 13 Kim CH, Kim JK, Kim HJ. , et al. Comparison of intranasal ciclesonide, oral levocetirizine, and combination treatment for allergic rhinitis. Allergy Asthma Immunol Res 2015; 7 (02) 158-166
  • 14 Price D, Kemp L, Sims E. , et al. Observational study comparing intranasal mometasone furoate with oral antihistamines for rhinitis and asthma. Prim Care Respir J 2010; 19 (03) 266-273
  • 15 Pampura AN, Papadopoulos NG, Spičák V, Kurzawa R. Evidence for clinical safety, efficacy, and parent and physician perceptions of levocetirizine for the treatment of children with allergic disease. Int Arch Allergy Immunol 2011; 155 (04) 367-378
  • 16 Motola D, Donati M, Biagi C. , et al. Safety profile of H1-antihistamines in pediatrics: an analysis based on data from VigiBase. Pharmacoepidemiol Drug Saf 2017; 26 (10) 1164-1171
  • 17 Chur V, Small CB, Stryszak P, Teper A. Safety of mometasone furoate nasal spray in the treatment of nasal polyps in children. Pediatr Allergy Immunol 2013; 24 (01) 33-38
  • 18 Affrime MB, Kosoglou T, Thonoor CM, Flannery BE, Herron JM. Mometasone furoate has minimal effects on the hypothalamic-pituitary-adrenal axis when delivered at high doses. Chest 2000; 118 (06) 1538-1546
  • 19 Delgado-Rodríguez M, Llorca J. Bias. J Epidemiol Community Health 2004; 58 (08) 635-641